Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

NCT05541367 · tracked via the Priya Life Science China tracker

Sponsor

Tongji Hospital

Phase

Observational

Started

2021-12-31

Last updated

2022-09-15

Condition(s) studied

Breast CancerTNBC - Triple-Negative Breast CancerEstrogen-receptor-negative Breast Cancer

Study summary

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * More than 18 years old * Patients with pathologically confirmed breast cancer * Sign the informed consent form Exclusion Criteria: * Pregnant women * Severe underlying diseases that cannot cooperate with PET examination

Primary outcome measure(s)

SUVmax — 5 years
SUVmax

Trial sites (1)

Facility	City	Region	Status
TongjiHospital	Wuhan	Hubei	Recruiting

More Tongji Hospital trials in China

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer Recruiting

Comparing Laparoscopic and Open Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas Enrolling by invitation

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance Recruiting

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases Active, not recruiting

Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery Starting soon

Other trials for the same condition

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05541367 on ClinicalTrials.gov ↗ ← All trials in China